Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 16, 2025

Fortinet Delivers Isolated Infrastructure Acceleration for the AI Factory with NVIDIA

View original at finance.yahoo.com
Fortinet Delivers Isolated Infrastructure Acceleration for the AI Factory with NVIDIA Fortinet, Inc. Collaboration integrates firewalling, segmentation, and policy enforcement directly into NVIDIA BlueField-accelerated infrastructure for higher performance, stronger isolation, and simpler operations SUNNYVALE, Calif…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Running FortiGate VM directly on NVIDIA BlueField-3 DPUs extends the model of infrastructure-offloaded services to include advanced security, allowing organizations to enforce firewalling, segmentation and zero-trust policies at line rate without impacting GPU workloads

    80% confidence

  • Integrating FortiGate VM on BlueField-3 DPU gives customers a practical way to keep security aligned with new performance demands by improving isolation, reducing latency, and simplifying consistent policy enforcement

    80% confidence

  • As enterprises are modernizing their data centers to support AI, private cloud and edge applications require much higher throughput than traditional workloads

    80% confidence

  • AI factories demand an entirely new class of secure, accelerated infrastructure

    80% confidence

  • Traditional host-based firewall architectures struggle to keep pace with the demands of AI workloads, edge services, agentic AI-era traffic, and multitenant isolation

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com